Fig. 2.
Demonstration of hrVEGF in mouse liver after treatment with hrVEGF. A, mice were treated with APAP (200 mg/kg i.p.) plus vehicle (PBS) or APAP plus hrVEGF (50 μg, s.c.) and sacrificed at the indicated times. hVEGF levels were significantly elevated at 2 and 4 h in mice treated with hrVEGF. B, mice were treated with APAP and received two doses of hrVEGF or vehicle and were sacrificed at the indicated times. hVEGF levels were significantly elevated at 18 h in mice treated with hrVEGF. hVEGF levels in PBS-treated mice were 0.0 pg/g in both experiments (data not shown). *, significant difference from APAP/veh groups, p < 0.05.